Apr 09, 2020
PHA121, the first orally available bradykinin B2-receptor antagonist, shows clinically relevant activity in a translational in vivo model
Jul 24, 2019
REGENXBIO Expands Pipeline Using NAV Vectors to Deliver Therapeutic Antibodies for the Treatment of Hereditary Angioedema and Neurodegenerative Diseases
Jun 19, 2019
Global Hereditary Angioedema (HAE) Markets, 2017-2018 & 2019-2026
Nov 19, 2018
Additional specialty drugs available through AllianceRx Walgreens Prime
Sep 25, 2018
Global Hereditary Angioedema Therapeutics Market 2018-2022: Market to Grow at a CAGR of 8.94% with BioCryst Pharmaceuticals, Cipla, CSL, Pharming Group & Shire Dominating
Jun 08, 2018
Global Hereditary Angioedema Market Forecast 2018-2028 - Visiongain Report
May 30, 2018
Asia-Pacific Hereditary Angioedema (HAE) Therapeutics Markets 2016-2018 & 2023
Apr 19, 2018
Prime Therapeutics Finds Drug Costs Drive Nearly Entire Cost of Care for Hereditary Angioedema
Mar 15, 2018
CSL Behring Receives Patient Impact Award For Subcutaneous Prophylactic Treatment To Prevent Hereditary Angioedema Attacks
Mar 13, 2018
CSL CEO Paul Perreault Calls on Industry to Improve Patients' Access to Medicines
Nov 17, 2017
Hereditary Angioedema - Epidemiology Forecast to 2025
Oct 29, 2017
Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting
Oct 24, 2017
New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Oct 24, 2017
Plasma Protease C1-inhibitor Treatment Market Worth US$7.9 Billion by 2025, Globally: Transparency Market Research
Aug 23, 2017
Hereditary Angioedema Market to be Worth US$3.81 Billion by 2025: Initiatives to Generate Awareness by Physicians and Patient Bodies Drive Growth
Jul 25, 2017
HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema
Jul 21, 2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])
Jun 23, 2017
FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema